CNBC Investing Club

AbbVie disappoints for the quarter as several promising drugs come up short

Richard Gonzalez, chairman and chief executive officer of AbbVie Inc., listens during a Senate Finance Committee hearing on drug pricing on Capitol Hill in Washington, D.C., U.S., on Tuesday, Feb. 26, 2019.
Getty Images

Club holding AbbVie (ABBV) reported a mixed first quarter Friday morning. 

On the top line, net revenue increased 4.1% to $13.54 billion, but that missed the consensus estimate on FactSet of $13.66 billion.